Sarpogrelate

Drug Profile

Sarpogrelate

Alternative Names: Anplag; MCI-9042

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Mitsubishi Chemical
  • Developer Mitsubishi Chemical; Mitsubishi Tanabe Pharma Corporation
  • Class Antiplatelets; Succinates; Vascular disorder therapies
  • Mechanism of Action Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Arterial occlusive disorders
  • Discontinued Cerebral infarction; Myocardial infarction; Pain; Raynaud's disease; Respiratory tract disorders; Stroke

Most Recent Events

  • 01 Oct 2007 Mitsubishi Pharma Corporation merged with Tanabe Seiyaku Co. Ltd to form Mitsubishi Tanabe Pharma Corporation
  • 11 May 2006 Discontinued - Phase-II for Pain in Japan (unspecified route)
  • 11 May 2006 Suspended - Phase-II for Arterial occlusive disorders in Europe (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top